Literature DB >> 32308883

Achieving Data Liquidity: Lessons Learned from Analysis of 38 Clinical Registries (The Duke-Pew Data Interoperability Project.

James E Tcheng1, Joseph P Drozda2, Davera Gabriel1, Anne Heath2, Rebecca W Wilgus1, Mary Williams1, Thomas A Windle1, John R Windle3.   

Abstract

BACKGROUND: To assess the current state of clinical data interoperability, we evaluated the use of data standards across 38 large professional society registries.
METHODS: The analysis included 4 primary components: 1) environmental scan, 2) abstraction and cross-tabulation of clinical concepts and corresponding data elements from registry case report forms, dictionaries, and / or data models, 3) cross-tabulation of same across national common data models, and 4) specifying data element metadata to achieve native data interoperability.
RESULTS: The registry analysis identified approximately 50 core clinical concepts. None were captured using the same data representation across all registries, and there was little implementation of data standards. To improve technical implementation, we specified 13 key metadata for each concept to be used to achieve data consistency.
CONCLUSION: The registry community has not benefitted from and does not contribute to interoperability efforts. A common, authoritative process to specify and implement common data elements is greatly needed. ©2019 AMIA - All rights reserved.

Year:  2020        PMID: 32308883      PMCID: PMC7153125     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  2 in total

1.  Need for a National Evaluation System for Health Technology.

Authors:  Jeffrey Shuren; Robert M Califf
Journal:  JAMA       Date:  2016-09-20       Impact factor: 56.272

2.  The Use of Clinical Registries in the United States: A Landscape Survey.

Authors:  Seth Blumenthal
Journal:  EGEMS (Wash DC)       Date:  2017-12-07
  2 in total
  1 in total

1.  Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders.

Authors:  Carla J Jonker; Sieta T de Vries; H Marijke van den Berg; Patricia McGettigan; Arno W Hoes; Peter G M Mol
Journal:  Drug Saf       Date:  2021-06-06       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.